Impact of an electronic medium delivery of warfarin education in a low income, minority outpatient population: a pilot intervention study.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
05 Aug 2019
Historique:
received: 21 01 2019
accepted: 25 07 2019
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 31 10 2019
Statut: epublish

Résumé

Warfarin is classified as a high-alert medication for ambulatory healthcare and safe guards for high-alert medications are necessary, including the practice of mandatory patient education. The high cost of hospitalizations related to adverse events combined with the average bleeding event rate of 7-8% in spite of routine patient education, suggests the importance of new approaches to standardized health education on warfarin. We sought to evaluate the impact of a warfarin educational video using an electronic tablet on patient knowledge and to determine patients' satisfaction with the use of an electronic tablet for educational purposes in outpatient clinics serving a low income, minority population. A warfarin educational video delivered on an electronic tablet (iPad) was delivered at two pharmacist-managed anticoagulation clinics to uninsured patients whose annual income is equal or less than two hundred percent below the poverty level were offered. Patients (n = 18) completed a pre-video and post-video knowledge test on warfarin before and after viewing the warfarin educational video on an electronic tablet and a follow-up test to measure the retention of knowledge and a patient satisfaction survey at 60 days. The primary outcome was change in knowledge test scores. Other outcome measures included adherence rates, adverse events, time in therapeutic INR range, and patient-reported satisfaction scores. The majority of patients were uninsured men taking warfarin for atrial fibrillation (n = 5). The median scores at post-video knowledge test and follow-up knowledge test were significantly higher than that for the pre-knowledge test (12 (11-12) vs. 10(8-11), p < 0.001). The study group had a 'time in therapeutic INR' range of 56.3%, a rate of adverse events of 24.5%, and a self-reported adherence rate to warfarin of 94.1%. The majority of patients also had positive responses to the patient satisfaction survey. Patient education delivered via iPad to facilitate knowledge of medication can serve as a useful tool for educating patients about warfarin and warfarin therapy. Use of an electronic medium may be a unique way to provide standard medication education to patients. The study was retrospectively registered with: NCT03650777 ; 9/18/18.

Sections du résumé

BACKGROUND BACKGROUND
Warfarin is classified as a high-alert medication for ambulatory healthcare and safe guards for high-alert medications are necessary, including the practice of mandatory patient education. The high cost of hospitalizations related to adverse events combined with the average bleeding event rate of 7-8% in spite of routine patient education, suggests the importance of new approaches to standardized health education on warfarin. We sought to evaluate the impact of a warfarin educational video using an electronic tablet on patient knowledge and to determine patients' satisfaction with the use of an electronic tablet for educational purposes in outpatient clinics serving a low income, minority population.
METHODS METHODS
A warfarin educational video delivered on an electronic tablet (iPad) was delivered at two pharmacist-managed anticoagulation clinics to uninsured patients whose annual income is equal or less than two hundred percent below the poverty level were offered. Patients (n = 18) completed a pre-video and post-video knowledge test on warfarin before and after viewing the warfarin educational video on an electronic tablet and a follow-up test to measure the retention of knowledge and a patient satisfaction survey at 60 days. The primary outcome was change in knowledge test scores. Other outcome measures included adherence rates, adverse events, time in therapeutic INR range, and patient-reported satisfaction scores.
RESULTS RESULTS
The majority of patients were uninsured men taking warfarin for atrial fibrillation (n = 5). The median scores at post-video knowledge test and follow-up knowledge test were significantly higher than that for the pre-knowledge test (12 (11-12) vs. 10(8-11), p < 0.001). The study group had a 'time in therapeutic INR' range of 56.3%, a rate of adverse events of 24.5%, and a self-reported adherence rate to warfarin of 94.1%. The majority of patients also had positive responses to the patient satisfaction survey.
CONCLUSIONS CONCLUSIONS
Patient education delivered via iPad to facilitate knowledge of medication can serve as a useful tool for educating patients about warfarin and warfarin therapy. Use of an electronic medium may be a unique way to provide standard medication education to patients.
TRIAL REGISTRATION BACKGROUND
The study was retrospectively registered with: NCT03650777 ; 9/18/18.

Identifiants

pubmed: 31382942
doi: 10.1186/s12889-019-7370-4
pii: 10.1186/s12889-019-7370-4
pmc: PMC6683532
doi:

Substances chimiques

Anticoagulants 0
Warfarin 5Q7ZVV76EI

Banques de données

ClinicalTrials.gov
['NCT03650777']

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1050

Références

Health Aff (Millwood). 2003 Jul-Aug;22(4):147-53
pubmed: 12889762
Br J Haematol. 2005 Apr;129(1):72-8
pubmed: 15801958
Ann Pharmacother. 2006 Apr;40(4):633-8
pubmed: 16551766
Health Educ Behav. 2006 Jun;33(3):352-73
pubmed: 16699125
Res Social Adm Pharm. 2005 Mar;1(1):40-59
pubmed: 17138465
Arch Intern Med. 2007 Feb 12;167(3):239-45
pubmed: 17296878
BMC Health Serv Res. 2008 Feb 14;8:40
pubmed: 18275605
Int J Psychiatry Med. 2009;39(2):113-32
pubmed: 19860071
Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):731-6
pubmed: 20583203
Prim Health Care Res Dev. 2012 Jan;13(1):42-7
pubmed: 21854695
J Prim Care Community Health. 2012 Jan 1;3(1):65-74
pubmed: 23804857
PLoS One. 2013 Sep 09;8(9):e74037
pubmed: 24040156
J Patient Saf. 2015 Sep;11(3):160-5
pubmed: 24522209
Genome Med. 2014 Feb 26;6(2):16
pubmed: 24571651
BMC Res Notes. 2015 Sep 10;8:429
pubmed: 26358332
Transl Behav Med. 2015 Dec;5(4):470-82
pubmed: 26622919
BMC Public Health. 2018 May 22;18(1):646
pubmed: 29788998
Thromb Haemost. 1993 Mar 1;69(3):236-9
pubmed: 8470047

Auteurs

Krista Heinrich (K)

Department of Clinical Pharmacy, Health Texas Provider Network, Baylor Scott & White Health, 2001 Bryan Street, Suite 2800, Dallas, TX, 75201, USA. Krista.Heinrich@BSWHealth.org.

Katherine Sanchez (K)

Center for Applied Health Research, Baylor Scott and White Research Institute, 8080 North Central Expressway, Suite 1050, Dallas, TX, 75206, USA.

Cecilia Hui (C)

Department of Clinical Pharmacy, Health Texas Provider Network, Baylor Scott & White Health, 2001 Bryan Street, Suite 2800, Dallas, TX, 75201, USA.

Kiara Talabi (K)

Department of Clinical Pharmacy, Health Texas Provider Network, Baylor Scott & White Health, 2001 Bryan Street, Suite 2800, Dallas, TX, 75201, USA.

Marlena Perry (M)

Department of Clinical Pharmacy, Health Texas Provider Network, Baylor Scott & White Health, 2001 Bryan Street, Suite 2800, Dallas, TX, 75201, USA.

Huanying Qin (H)

Department of Quantitative Sciences, Baylor Scott and White Health, 8080 N. Central Expressway, Suite 900, Dallas, TX, 75206, USA.

Hoa Nguyen (H)

Department of Clinical Pharmacy, Health Texas Provider Network, Baylor Scott & White Health, 2001 Bryan Street, Suite 2800, Dallas, TX, 75201, USA.
Department of Quantitative Sciences, Baylor Scott and White Health, 8080 N. Central Expressway, Suite 900, Dallas, TX, 75206, USA.

Amulya Tatachar (A)

Department of Clinical Pharmacy, Health Texas Provider Network, Baylor Scott & White Health, 2001 Bryan Street, Suite 2800, Dallas, TX, 75201, USA.
University of North Texas System College of Pharmacy, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76107, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH